Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
September 14 2022 - 9:00AM
Parexel, a leading global clinical research organization (CRO),
today announced the promotions of Peyton Howell to the
newly-created role of Chief Operating and Growth Officer and Amy
McKee, MD, to Chief Medical Officer and Global Head, Oncology
Center of Excellence. These moves are designed to strengthen the
company’s medical and scientific focus and support its continued
record growth through closer alignment of all aspects of strategy,
sales and delivery to delight customers, build repeat business and
lead the market in the next phase of drug development
transformation.
As Chief Operating and Growth Officer, Ms. Howell will lead
Parexel’s operational delivery, strategy and growth. She joined
Parexel in May 2018 and most recently was President, Consulting and
Chief Commercial & Strategy Officer, leading the company to
record new business growth and creation of a patient-focused
strategy. In addition to providing strategic oversight for the
rebranding of Parexel in 2019, Ms. Howell was a key architect in
the launch of the organization’s new Business Strategy and has
consistently led Parexel’s global Biotech and Enterprise Commercial
teams to record new business growth.
“As the market evolves, we continuously review our structure to
ensure Parexel remains well positioned to deliver integrated and
innovative solutions for our patients and customers,” said Chief
Executive Officer Jamie Macdonald. “The promotion of Peyton Howell
to this expanded role is a natural extension of her significant
contributions to the growth of Parexel over the past four years and
along with her tremendous energy and passion for serving our
customers, patients and colleagues. Broadening the scope of her
strategic leadership to now include our operational delivery units
further enhances the support we’re able to provide to our
customers’ development programs. We’re excited for this next
chapter and wish both Peyton and Amy every success in their new
roles.”
Ms. Howell has more than 25 years of leadership experience in
the healthcare industry, including several leadership positions
with AmerisourceBergen, a Fortune 20 company, most recently as
President for Health Systems and Specialty Care Solutions, a $50B
business unit. Currently she represents Parexel on the Board of
Directors for the Association of Clinical Research Organizations
(ACRO) and serves on the Board of Directors of Tandem Diabetes Care
(NASDAQ:TNDM), a medical device manufacturer. Ms. Howell holds a
Masters’ in Healthcare Administration (MHA) from The Ohio State
University and in 2020 was named a Luminary by the Healthcare
Businesswomen’s Association (HBA).
As Chief Medical Officer and Global Head, Oncology Center of
Excellence, Dr. McKee will provide patient-focused medical and
scientific leadership globally in support of the company’s Phase I
to IV clinical trials. With nearly 20 years of FDA regulatory,
clinical research, bench science and clinical medicine experience,
she will provide strategic oversight for the company’s
therapeutic/medical and scientific centers of excellence to drive
growth and innovation, including collaboration with key
stakeholders to strengthen Parexel as a collaborative drug
development partner and establish market-leading, patient-centered
teams.
“We are thrilled to appoint Amy as our new Chief Medical Officer
as we expand our therapeutic expertise to align with the
fastest-growing areas of patient need,” added Peyton Howell, Chief
Operating and Growth Officer. “With her proven track record in the
design and implementation of complex and innovative clinical
development programs across a broad spectrum of therapeutic areas —
with a particular specialization in oncology — we have no doubt Amy
will have a tremendous impact as we accelerate innovations to bring
new therapies to patients.”
Dr. McKee joined Parexel in February 2019 as Vice President,
Regulatory Consulting Services and prior to joining the company
spent 11 years with the FDA during which time she served as Deputy
Center Director, Oncology Center of Excellence; Supervisory
Associate Director, Office of Hematology and Oncology Products
(OHOP) and Deputy Office Director of OHOP. She is a board-certified
Pediatric Hematologist-Oncologist with specific expertise in the
treatment of neuroblastoma and holds a Doctor of Medicine degree
from the Tulane University School of Medicine in New Orleans, La.
Dr. McKee currently serves on the Board of Directors for BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX).
About ParexelOne of the largest clinical
research organizations, Parexel supports the development of
innovative new medicines to improve the health of patients. We
provide services to help life sciences and biopharmaceutical
customers everywhere transform scientific discoveries into new
treatments. From decentralized clinical trials to regulatory
consulting services to leveraging real world insights, our
therapeutic, technical and functional ability is underpinned by a
deep conviction in what we do. For more information,
visit parexel.com and follow us
on LinkedIn, Twitter, and Instagram.
MEDIA Lori Preuit Dorer+1 513 496
8121Lori.Dorer@parexel.com
Danaka Williams+1 984 298 4207Danaka.Williams@parexel.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024